Imara Inc (NASDAQ: IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.
In addition to $250,000 previously paid by Cardurion upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront payment of $34.75 million and $60 million as milestone payments.
In case of termination, the company would be obligated to pay a fee of $1.5 million Cardurion.
In April, Imara posted interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia.
No meaningful benefit was observed in transfusion burden in either tovinontrine group compared to the placebo in the beta-thalassemia study.
Imara announced discontinuing the Ardent and Forte trials and further developing tovinontrine in sickle cell disease and beta-thalassemia.
Price Action: IMRA shares are up 37.60% at $1.61 during the premarket session on the last check Wednesday.
See more from Benzinga
Top Financial Stories Wednesday, September 07: Musk Cited Putin Worries To Delay Twitter Deal, Apple To Defend Move Of Selling iPhones Without Charger, Deutsche Bank CEO Signals Recession Risks And More..
Baker Hughes To Simplify Organizational Structure With Two Business Units
Tesla Motors (TSLA) – If You Invested $100 When Elon Musk First Tweeted About Dogecoin, Here's How Much Y
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
